Cochlear

Cochlear, founded in 1981, is a global leader in the medical device and manufacturing sectors, specializing in implantable hearing solutions. Headquartered in New South Wales, Australia, the company designs, manufactures, and supplies advanced auditory implants. Its core product portfolio includes the Nucleus cochlear implant, the Hybrid electro-acoustic implant, and the Baha bone conduction implant, addressing profound hearing loss and enabling individuals to reconnect with sound. With a significant global presence, Cochlear operates across 22 locations worldwide, demonstrating its commitment to accessibility and innovation in audiology. Learn about Cochlear's global headquarters for detailed geographic information.

Operating with a workforce of 5,000-10,000 employees, Cochlear is dedicated to improving the quality of life for people with hearing impairments. The company's extensive research and development efforts drive continuous advancements in implantable hearing technology, ensuring cutting-edge solutions for patients. Cochlear's commitment extends beyond product development to comprehensive patient support and rehabilitation services. Meet Cochlear's team to understand the expertise driving their mission. Their strategic focus on innovation and patient outcomes positions them as a key player in the medical technology landscape.

Cochlear's market position is further solidified by its extensive product range and its role in advancing audiology. The company competes within the highly specialized medical device industry, focusing on restorative hearing solutions. Its sustained investment in technology and global reach underscore its mission to help more people hear. The company's ticker symbol is ASX: COH, reflecting its public trading status. Cochlear's dedication to innovation and patient care has established it as a pivotal entity in theView more...